Literature DB >> 23645585

Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission.

Kevin K Ariën1, Muthusamy Venkatraj, Johan Michiels, Jurgen Joossens, Katleen Vereecken, Pieter Van der Veken, Saïd Abdellati, Vicky Cuylaerts, Tania Crucitti, Leo Heyndrickx, Jan Heeres, Koen Augustyns, Paul J Lewi, Guido Vanham.   

Abstract

OBJECTIVES: Pre-exposure prophylaxis and topical microbicides are important strategies in the prevention of sexual HIV transmission, especially since partial protection has been shown in proof-of-concept studies. In search of new candidate drugs with an improved toxicity profile and with activity against common non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV, we have synthesized and investigated a library of 60 new diaryltriazine analogues.
METHODS: From this library, 15 compounds were evaluated in depth using a broad armamentarium of in vitro assays that are part of a preclinical testing algorithm for microbicide development. Antiviral activity was assessed in a cell line, and in primary human cells, against both subtype B and subtype C HIV-1 and against viruses resistant to therapeutic NNRTIs and the candidate NNRTI microbicide dapivirine. Toxicity towards primary blood-derived cells, cell lines originating from the female reproductive tract and female genital microflora was also studied. RESULTS AND
CONCLUSIONS: We identified several compounds with highly potent antiviral activity and toxicity profiles that are superior to that of dapivirine. In particular, compound UAMC01398 is an interesting new candidate that warrants further investigation because of its superior toxicity profile and potent activity against dapivirine-resistant viruses.

Entities:  

Keywords:  NNRTIs; cytotoxicity; lactobacilli; microbicides; triazines

Mesh:

Substances:

Year:  2013        PMID: 23645585     DOI: 10.1093/jac/dkt166

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Investigational reverse transcriptase inhibitors for the treatment of HIV.

Authors:  Theodore J Cory; Narasimha M Midde; Pss Rao; Santosh Kumar
Journal:  Expert Opin Investig Drugs       Date:  2015-06-19       Impact factor: 6.206

2.  Cross-Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention.

Authors:  Jordan K Kyongo; Tania Crucitti; Joris Menten; Liselotte Hardy; Piet Cools; Johan Michiels; Sinead Delany-Moretlwe; Mary Mwaura; Gilles Ndayisaba; Sarah Joseph; Raina Fichorova; Janneke van de Wijgert; Guido Vanham; Kevin K Ariën; Vicky Jespers
Journal:  Clin Vaccine Immunol       Date:  2015-03-11

3.  CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge.

Authors:  Kevin K Ariën; Françoise Baleux; Delphine Desjardins; Françoise Porrot; Yves-Marie Coïc; Johan Michiels; Kawthar Bouchemal; David Bonnaffé; Timothée Bruel; Olivier Schwartz; Roger Le Grand; Guido Vanham; Nathalie Dereuddre-Bosquet; Hugues Lortat-Jacob
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

4.  Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  Kaijun Jin; Minjie Liu; Chunlin Zhuang; Erik De Clercq; Christophe Pannecouque; Ge Meng; Fener Chen
Journal:  Acta Pharm Sin B       Date:  2019-10-17       Impact factor: 11.413

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.